Get started

Biotech

NTEC Jumped above $0.70 since falling apartWhat are the thoughts here? News? -NOPE...pure momentum today? Biggest volume it's had since the big drop day so what can explain this move? "Intec Pharma Ltd. is a biotechnology company that creates drugs using its Accordion Pill technology. This technology is designed to improve the safety of drugs when taken orally. The company currently has 5 treatments in its pipeline with AP-CD/LD in Phase 3 trials.Over the last 2 trading sessions, Intec’s stock price has seen significant gains. On August 27th the stock price rose 14.8% and in premarket trading, on the 28th it has risen another 15%. These percentage gains allowed the biotech penny stock to go from $0.45 to $0.61." Original Article: 4 Penny Stocks To Watch Under $4 NASDAQ:NTEC
N
by PennyStocks101
Repeating Pattern #VolatilityWatchNeckline (outlined in blue) for inverse Head and shoulders. Harmonic Cypher pattern @786 retracement, where ADMA bounced. RSI moving up with trend, showing strong accumulation (Bulls in control) Highlighted in the blue box's is a pattern that I've been watching for awhile now. As you can see, they are very similar and just so happens that today's close was pushing up against the top of the neckline for the head and shoulders. Seems ADMA could have a significant move within the next few days Also, for those who aren't familiar with ADMA, they do have an announcement/PR for one of their lead products - Bivigam, to launch... Coming soon =) Please like and follow so I can continue finding awesome charts. Thank you in advance everyone d=) Disclosure: I am long ADMA. This is not a note to buy or sell, please do your homework before investing.
NASDAQ:ADMALong
by follow_the_money
$AMPE Ampio Pharmaceuticals Inc A Good Risk/Reward PlayWe are really liking the chart on $AMPE. You have the rounding bottom and there looks to be accumulation going on. Currently trading at $.62 a share, the 52-week low is $.35 a share. We believe $AMPE has breakout written all over it and there is an upcoming catalyst that can send the stock flying higher. The company is due to hear from the FDA shortly. Here's what the company said last month in its update: Ampio Pharmaceuticals has been in contact with the U.S. Food and Drug Administration (FDA) regarding the Special Protocol Assessment (SPA) following its re-submission of a revised protocol for AP-013, which the Company believes implements all of the Agency's recommendations provided since the beginning of the SPA review cycle. The Agency confirmed that it would make every effort to expedite this review, however due to a heavy workload, they were not able to commit to providing a response to the Company's SPA re-submission earlier than the 45-day window outlined in the Guidance for Industry Special Protocol Assessment, leading the Company to expect the response will be in mid-June rather than late May 2019, as previously predicted. There is some debate on social channels as to when this news will hit the tape. Some are saying any day now, while others are saying after the July 4th holiday. As always, trade with caution and use protective stops. Good luck to all!
ALong
by InsiderFinancial
$VIVE Viveve Medical Inc Has Gaps To Fill$VIVE has come across our screen after the company received 510k approval of its Viveve System 2.0, which is its second generation product. This is a big development and explains why the stock is up 24% today. We believe there's a lot more room for $VIVE to run as there are gaps above that need to be filled. There's $1.50 to $1.84 and then $2.50 to $3.18 Furthermore, the risk/reward looks good. Can go Long here with a stop at new 52-week lows at $.41 a share. As always, trade with caution and use protective stops. Good luck to all! About Viveve Viveve Medical, Inc. is a medical technology company focused on women's intimate health. Viveve is committed to advancing new solutions to improve women's overall well-being and quality of life. The internationally patented Viveve® System incorporates cryogen-cooled monopolar radiofrequency (CMRF) technology to uniformly deliver volumetric heating while gently cooling surface tissue to generate neocollagenesis in a single in-office session. International regulatory approvals and clearances have been received for vaginal laxity and/or improvement in sexual function indications in over 50 countries. Viveve is conducting VIVEVE II, a multicenter, randomized, double-blind, sham-controlled clinical trial to assess improvement of sexual function in women following vaginal childbirth. Completion of full 250 subject enrollment was announced in early March 2019. If successful, VIVEVE II results could support a marketing application for a new U.S. commercial indication. Currently, in the United States, the Viveve® System is cleared by the FDA for use in general surgical procedures for electrocoagulation and hemostasis. Viveve has fully enrolled LIBERATE-International, one of two planned independent, multicenter, randomized registration trials for the improvement of stress urinary incontinence in women and plans to re-submit an IDE to the FDA for LIBERATE-U.S. after conducting certain safety testing. The results of these two trials, if successful, could support marketing applications in the U.S. and over 30 countries around the world for this new commercial indication.
VLong
by InsiderFinancial
Deja Vu?Almost exactly one-year ago NDRA received this same form 8-K "Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing." *Shortly after recieving this notice, NDRA's Price shot up dramatically. In September, ENDRA Life Sciences is planning to present the final results of the #Robarts study in conjunction with the upcoming EASL-NAFLD Summit in Seville, Spain. Pattern is very similar to last year's notification. Disclosure: I am long NDRA. This is not a note to buy or sell. Please do your own Homework before investing.
NASDAQ:NDRALong
by follow_the_money
(Nasdaq: CODX) Bullish signal - GOLDEN CROSSThis could be the next NASDAQ Biotech ready to move in a big way, here's why... (Nasdaq: CODX) displaying the Holy grail of Bullish signals - a GOLDEN CROSS. The 50 Day EMA just crossed the 200 Day EMA, which most of you know by now is a bullish signal that indicates a potential breakout is on the Horizon. Here Is Another Potential "Breakout Catalyst" In Play Wall Street Analysts at H.C. Wainwright & Maxim Group have both given Co-Diagnostics (Nasdaq: CODX) Buy rating with a $2.00 Price Target, almost double its price at Fridays close, suggesting the stock has a potential upside of +80%.
NASDAQ:CODX
by JamieCharts
Bearish Butterfly SGEN has beat biotech averages significantly the past few months and has come to meet my $80 pt which also happens to make a bearish harmonic butterfly pattern. This could have a little more upside as it tests $80-81 but risk/reward would suggest a potential double top that can take this down quite a bit in a short amount of time. If I was short I would be looking to start a position. According to the bearish setup SGEN should find 50 -618 retracement before next ER bringing SGEN down to around the $69 mark. As I have outlined in this setup, SGEN is still making higher lows on long-term chart and after retracing back to $69, should see continue uptrend to ~$84 (assuming another positive ER or catalyst). Tip - Even if you rely mostly on company fundamentals, you should be aware of support/ resistance levels. Please Follow, like, comment, and share so I can continue finding awesome trades. Thank you in advance >+) Find me on Twitter or Instagram @VolatilityWatch Disclosure: I do not own a position in SGEN. I may buy/sell within the next 72 hours. This is not a note to buy or sell, please do your homework before investing.
SShort
by follow_the_money
G1 Therapeutics RALLYEarnings/News Co's lead cancer therapy, trilaciclib, gets FDA's "breakthrough therapy" status, which is meant to speed up review of drugs that treat life-threatening conditions GTHX says it will present new data on three of its drugs, including trilaciclib, at an upcoming conference in September FDA's move is a recognition that clinical data presented so far reflects the potential for trilaciclib to address an urgent unmet medical need - Cowen & Co Analyst Actions JP Morgan Upgrades G1 Therapeutics to Overweight From Neutral, PT Raised to $45 From $38
GLong
by dorfmanmaster
$MACK Merrimack Pharmaceuticals Inc Heading HigherShareholders of $MACK are getting a $20 million special dividend. The special dividend is payable on September 5, 2019 to stockholders of record as of the close of business on August 28, 2019. The ex-dividend date for the special dividend will be September 6, 2019, the first trading day following the payment date. Stockholders of record on the record date who sell their shares prior to the ex-dividend date will not receive the special dividend. Based on the current number of shares outstanding, the special dividend will be approximately $1.50 per common share; this amount may vary based on the number of outstanding shares as of the record date. "The authorization of a special dividend higher than the range that we had initially estimated is an important step in implementing the strategic plan that we announced on May 30, 2019 and reflects our success in restructuring the Company and the recent closing of the sale of certain programs to 14ner Oncology, Inc.," said Gary Crocker, Chairman of Merrimack's Board of Directors. "Our remaining cash balance is anticipated to support operations into 2027, when we estimate the longest-term potential Ipsen milestone may be achieved." About Merrimack Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts that is entitled to receive up to $455.0 million in contingent milestone payments related to its sale of ONIVYDE® to Ipsen S.A. in April 2017 and up to $54.5 million in contingent milestone payments related to its sale of anti-HER3 programs to 14ner Oncology, Inc. in July 2019. The Company is seeking potential acquirers for its remaining preclinical and clinical assets. Why is the $20 million special dividend significant? Because $MACK has a market cap of just $80 million. $MACK looks to be a buy and hold. As always, use protective stops and trade with caution. Good luck to all!
MLong
by InsiderFinancial